Inhibrx Biosciences Inc (INBX)

NASDAQ
Currency in USD
13.83
-0.11(-0.79%)
Real-time Data
INBX Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
13.1514.06
52 wk Range
10.8018.95
Key Statistics
Edit
Prev. Close
13.94
Open
13.53
Day's Range
13.15-14.06
52 wk Range
10.8-18.95
Volume
27.04K
Average Vol. (3m)
92.46K
1-Year Change
-
Book Value / Share
12.33
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INBX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
15.00
Upside
+8.46%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Inhibrx Biosciences Inc Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

Employees
169

Inhibrx Biosciences Inc SWOT Analysis


Analyst Outlook
Discover analysts' cautious optimism on Inhibrx, with a balanced view reflected in market performance ratings and an average price target range of $40-$60
Market Potential
Learn how Inhibrx's novel therapies could capture significant market share in underserved oncology indications, with potential first-mover advantage in chondrosarcoma
Financial Fortitude
Delve into Inhibrx's robust financial position, bolstered by a $2.2 billion Sanofi deal, providing runway for multiple clinical programs through key milestones
Pipeline Promise
Explore Inhibrx's innovative oncology pipeline, featuring ozekibart for chondrosarcoma and INBRX-106 for head and neck cancer, poised for pivotal data readouts
Read full SWOT analysis

Compare INBX to Peers and Sector

Metrics to compare
INBX
Peers
Sector
Relationship
P/E Ratio
0.1x−0.2x−0.6x
PEG Ratio
-−0.010.00
Price / Book
1.5x0.3x2.6x
Price / LTM Sales
1,017.7x10.3x3.0x
Upside (Analyst Target)
7.6%235.0%51.6%
Fair Value Upside
Unlock4.7%9.3%Unlock

Analyst Ratings

0 Buy
2 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 15.00
(+8.46% Upside)

Earnings

Latest Release
Mar 17, 2025
EPS / Forecast
-3.09 / -1.44
Revenue / Forecast
100.00K / --
EPS Revisions
Last 90 days

People Also Watch

8.74
STOK
-2.89%
1.25
IGMS
+1.63%
3.640
PSNL
-4.21%
10.52
TXG
-2.23%
8.23
NUS
-0.24%

FAQ

What Is the Inhibrx Biosciences (INBX) Stock Price Today?

The Inhibrx Biosciences stock price today is 13.83

What Stock Exchange Does Inhibrx Biosciences Trade On?

Inhibrx Biosciences is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Inhibrx Biosciences?

The stock symbol for Inhibrx Biosciences is "INBX."

What Is the Inhibrx Biosciences Market Cap?

As of today, Inhibrx Biosciences market cap is 201.79M.

What is Inhibrx Biosciences Earnings Per Share?

The Inhibrx Biosciences EPS is 119.39.

What Is the Next Inhibrx Biosciences Earnings Date?

Inhibrx Biosciences will release its next earnings report on May 28, 2025.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.